Areteia Therapeutics Stock
Areteia Therapeutics is developing oral drugs to treat eosinophilic asthma. Its lead product, dexpramipexole, inhibits the maturation of eosinophils, offering a potential treatment for patients with this severe asthma form, enhancing their disease management.
Founded: 2022
For more Areteia Therapeutics stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Jorge Bartolome Co-Founder & Chief Executive Officer |
| Christopher Courts Co-Founder & Chief Financial Officer |
| Peter Wijngaard Ph.D. Chief Development Officer |
| Calman Prussin MD Chief Scientific Officer |
| Mark Kreston Chief Commercial Officer |
| Eric Bradford MD Co-Founder & Chief Medical Officer |
| Robin Walker JD Co-Founder, Chief Legal Officer & Corporate Secretary |
